Wasik M A, Vonderheid E C, Bigler R D, Marti R, Lessin S R, Polansky M, Kadin M E
Department of Pathology, Beth Israel Hospital, Boston, Mass, USA.
Arch Dermatol. 1996 Jan;132(1):42-7.
The serum concentration of soluble alpha-chain receptor for interleukin-2 (sIL-2R) was determined in 101 patients with cutaneous T-cell lymphoma (CTCL).
The serum concentration of sIL-2R correlates positively with CTCL tumor burden as determined by several clinical parameters (ie, clinical subtype of disease, extent of skin involvement, T rating, and stage), by serum lactate dehydrogenase concentration, and by Sézary cell counts in erythrodermic disease. The median value of sIL-2R in erythrodermic CTCL was more than threefold higher than that of classic mycosis fungoides (MF). The proportion of patients with elevated sIL-2R concentration (> 1000 U/mL) also increased in CTCL in a similar fashion according to the clinical type of disease (MF patch phase, 15%; MF plaque phase, 33%; MF tumor phase, 47%; and erythrodermic variants, 90%). However, no correlation was found between sIL-2R serum concentration and expression of membrane-bound IL-2R alpha chain (CD25) on lymphoid cells in skin lesions and peripheral blood. Significantly, multivariate analysis of various prognostic factors demonstrated that in erythrodermic CTCL, sIL-2R serum concentration correlated best with survival and was a better predictor of prognosis than stage, Sézary cell counts, or lactate dehydrogenase values.
These findings document the usefulness of the measurement of the sIL-2R serum concentration to determine tumor burden and prognosis in patients with CTCL.
对101例皮肤T细胞淋巴瘤（CTCL）患者测定了白细胞介素-2可溶性α链受体（sIL-2R）的血清浓度。
sIL-2R的血清浓度与CTCL肿瘤负荷呈正相关，肿瘤负荷由多个临床参数（即疾病的临床亚型、皮肤受累范围、T分级和分期）、血清乳酸脱氢酶浓度以及红皮病型疾病中的Sezary细胞计数确定。红皮病型CTCL中sIL-2R的中位数比经典蕈样肉芽肿（MF）高3倍以上。根据疾病的临床类型，CTCL中sIL-2R浓度升高（>1000 U/mL）的患者比例也以类似方式增加（MF斑块期，15%；MF斑块期，33%；MF肿瘤期，47%；红皮病型变异型，90%）。然而，未发现sIL-2R血清浓度与皮肤病变和外周血中淋巴细胞上膜结合IL-2Rα链（CD25）的表达之间存在相关性。值得注意的是，对各种预后因素的多变量分析表明，在红皮病型CTCL中，sIL-2R血清浓度与生存率的相关性最佳，并且比分期、Sezary细胞计数或乳酸脱氢酶值更能预测预后。
这些发现证明了测定sIL-2R血清浓度对确定CTCL患者的肿瘤负荷和预后的有用性。
